Methods of inhibiting B lymphocytes using antibodies to Neutrokine-alpha
First Claim
1. A method of inhibiting B lymphocytes comprising administering an effective amount of an antibody that binds a protein whose amino acid sequence isMDDSTEREQS RLTSCLKKRE EMKLKECVSI LPRKESPSVR SSKDGKLLAA TLLLALLSCC LTVVSFYQVA ALQGDLASLR AELQGHHAEK LPAGAGAPKA GLEEAPAVTA GLKIFEPPAP GEGNSSQNSR NKRAVQGPEE TVTQDCLQLI ADSETPTIQK GSYTFVPWLL SFKRGSALEE KENKILVKET GYFFIYGQVL YTDKTYAMGH LIQRKKVHVF GDELSLVTLF RCIQNMPETL PNNSCYSAGI AKLEEGDELQ LAIPRENAQI SLDGDVTFFG ALKLL (SEQ ID NO:
- 2)wherein B lymphocytes are inhibited.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to a novel Neutrokine-alpha, and a splice variant thereof designated Neutrokine-alphaSV, polynucleotides and polypeptides which are members of the TNF family. In particular, isolated nucleic acid molecules are provided encoding the human Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides, including soluble forms of the extracellular domain. Neutrokine-alpha and/or Neutrokine-alphaSV polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of Neutrokine-alpha and/or Neutrokine-alphaSV activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
-
Citations
102 Claims
-
1. A method of inhibiting B lymphocytes comprising administering an effective amount of an antibody that binds a protein whose amino acid sequence is
MDDSTEREQS RLTSCLKKRE EMKLKECVSI LPRKESPSVR SSKDGKLLAA TLLLALLSCC LTVVSFYQVA ALQGDLASLR AELQGHHAEK LPAGAGAPKA GLEEAPAVTA GLKIFEPPAP GEGNSSQNSR NKRAVQGPEE TVTQDCLQLI ADSETPTIQK GSYTFVPWLL SFKRGSALEE KENKILVKET GYFFIYGQVL YTDKTYAMGH LIQRKKVHVF GDELSLVTLF RCIQNMPETL PNNSCYSAGI AKLEEGDELQ LAIPRENAQI SLDGDVTFFG ALKLL (SEQ ID NO: - 2)
wherein B lymphocytes are inhibited. - View Dependent Claims (4, 5, 6, 7, 8, 9, 10, 11, 12, 13)
- 2)
-
2. A method of inhibiting B lymphocyte proliferation comprising administering an effective amount of an antibody that binds Neutrokine-alpha (SEQ ID NO:
- 2), wherein B lymphocyte proliferation is inhibited.
-
3. A method of inhibiting B lymphocyte differentiation comprising administering an effective amount of an antibody that binds Neutrokine-alpha (SEQ ID NO:
- 2), wherein B lymphocyte differentiation is inhibited.
- 14. A method of treating an autoimmune disease or disorder comprising administering to an individual, an effective amount of an antagonistic antibody or portion thereof that specifically binds a protein consisting of the amino acid sequence of amino acid residues 134-285 of SEQ ID NO:
- 37. A method of treating rheumatoid arthritis comprising administering to an individual, an effective amount of an antagonistic antibody or portion thereof that specifically binds a protein consisting of the amino acid sequence of amino acid residues 134-285 of SEQ ID NO:
-
46. A method of inhibiting B lymphocyte proliferation, differentiation or survival comprising administering to an individual or a cell culture containing B lymphocytes, an effective amount of an antagonistic antibody or portion thereof that specifically binds a protein consisting of an amino acid sequence selected from the group consisting of:
-
(a) the amino acid sequence of amino acid residues n to 285 of SEQ ID NO;
2, where n is an integer in the range of 2-190;(b) the amino acid sequence of amino acid residues 1 to m of SEQ ID NO;
2, where m is an integer in the range of 274 to 284; and(c) the amino acid sequence of amino acid residues n to m of SEQ ID NO;
2, where n is an integer in the range of 2-190 and m is an integer in the range of 274-284. - View Dependent Claims (47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)
-
- 58. A method of inhibiting B lymphocyte proliferation, differentiation, or survival comprising administering to an individual or a cell culture containing B lymphocytes, an effective amount of an antagonistic antibody or portion thereof that specifically binds a protein consisting of the amino acid sequence of amino acid residues 134-285 of SEQ ID NO:
-
67. A method of treating an autoimmune disease or disorder comprising administering to an individual, an effective amount of an antagonistic antibody or portion thereof that specifically binds to an isolated recombinant Neutrokine-a protein purified from a cell culture wherein the cells in said cell culture comprise a polynucleotide encoding amino acids 1-285 of SEQ ID NO:
- 2 operably associated with a regulatory sequence that controls gene expression.
- View Dependent Claims (68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82)
-
83. A method of treating rheumatoid arthritis comprising administering to an individual, an effective amount of an antagonistic antibody or portion thereof that specifically binds to an isolated recombinant Neutrokine-a protein purified from a cell culture wherein the cells in said cell culture comprise a polynucleotide encoding amino acids 1-285 of SEQ ID NO:
- 2 operably associated with a regulatory sequence that controls gene expression.
- View Dependent Claims (84, 85, 86, 87, 88, 89, 90, 91)
- 92. A method of treating an autoimmune disease in an animal comprising administering a therapeutically effective amount of an anti-Neutrokine-alpha antibody that binds to human Neutrokine alpha polypeptide having the amino acid sequence of SEQ ID NO:
Specification